Please login to the form below

Not currently logged in
Email:
Password:

Ernst and Young

This page shows the latest Ernst and Young news and features for those working in and with pharma, biotech and healthcare.

R&D productivity still a big problem for biopharma

R&D productivity still a big problem for biopharma

The latest Beyond Borders report from Ernst &Young has plenty of positive and negative news, but on balance concludes the industry had a good year.  Revenue for US and European biotechs ... such as "understanding consumer behaviour, brand building, big

Latest news

  • Ernst & Young launches digital health innovation programme Ernst & Young launches digital health innovation programme

    Ernst &Young (EY) has launched a digital innovation programme to support and accelerate the use of technologies in health and social care. ... and which also make life easier for patients, their families and their carers.”.

  • HBA's new UK chapter to look at 'more than medicine' HBA's new UK chapter to look at 'more than medicine'

    Ernst &Young, Abbott and McKinsey. ... in difficult times, their tips on how to get ahead, and the important things to focus on.

  • Extent of biotech's vulnerability revealed

    A global survey of the biotech industry conducted by Ernst &Young has confirmed that the global financial crisis has adversely affected the capital invested in biotech companies. ... Ernst &Young's annual 'Survival index', released today, predicts that

  • The butterfly effect

    The role of marketing in both clinical trial activity and post-marketing studies. ... industry. The author. John Smart is a partner at Ernst &Young, Forensic Investigations and Dispute Advisory Services.

  • Searching for the best

    Patent expirations:In 2005, Ernst &Young reported that USD 23bn worth of products lost patent protection, representing the highest ever dollar value recorded. ... Ernst &Young reported that the collective market capitalisation of the top 360 public

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Ernst and Young in its report Beyond Borders also reports declines in volumes of M&A and strategic alliance deals in 2016. ... This referred to the CAR-T therapy, Kymriah, from Novartis for treating a form of acute lymphoblastic leukaemia in children and

  • Pharma deals in March 2015 Pharma deals in March 2015

    Pharmacyclics filled the bill. Table 1: Company and product acquisition deals in March. ... In 2014 according to Ernst and Young's report Firepower fireworks the aggregate value of biopharma deals in 2014 was over $200bn compared to around $80bn the year

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Fishawack appoints Jenifer Kirkland as CFO Fishawack appoints Jenifer Kirkland as CFO

    Kirkland previous positions at Ernst and Young, BT, Pearson and was most recently chief financial officer for life sciences consultancy Kinapse. ... Dennis said: “Jenifer’s experience and leadership will be invaluable to scaling up our finance

  • Chase adds former Allergan execs to leadership team Chase adds former Allergan execs to leadership team

    Most recently, Giacobello served as vice president of finance for global research and development at Allergan, and has held financial positions at Black &Decker and Ernst &Young. ... Meanwhile, Gary Charbonneau (pictured below) has been appointed as

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics